New drug cocktail shows promise in tough lung cancers
NCT ID NCT04924192
First seen Apr 20, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, China
-
The First Hospital of Lanzhou University
Lanzhou, Gansu, 730000, China
-
The Second Affiliated Hospital of PLA Air Force Military Medical University
Xi’an, Shanxi, 710038, China
-
West China Hospital of Sichuan University
Chengdou, Sichuan, 610041, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650011, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.